Royalty Pharma plc (RPRX) Adds to IPO Gains
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Royalty Pharma plc (RPRX) IPO Opens 57% Higher
June 16, 2020 12:07 PM EDTToday's IPO for Royalty Pharma plc (NASDAQ: RPRX) opened for trading at $44 after pricing 77,681,670 shares of its Class A ordinary shares at $28.
The underwriters have a 30-day option to purchase up to an additional 11,652,250 Class A ordinary shares from the company.
J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC, Citigroup and UBS Investment Bank are acting as joint lead book-running... More
